about
Partial nephrectomy versus radical nephrectomy for clinically localized renal massesIntravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerDynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.The use of preoperative targeted molecular therapy to allow nephron sparing for T1b tumors.Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature.Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC).Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.Prospects and progress of immunotherapy for bladder cancer.Organ Preservation is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinoma - Results of a Comprehensive Multicenter Study.Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma.Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Prognostic Implications of Immunohistochemical Biomarkers in Non-Muscle-Invasive Bladder Cancer and Muscle-Invasive Bladder Cancer.Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract.The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis.Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy.Should patients newly diagnosed with bladder cancer be screened for lung cancer?Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma.Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate CancerPreoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus.TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma.Surgical management of renal cell carcinoma.Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract.Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort.Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.The Rho GTPase signalling pathway in urothelial carcinoma.Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
P50
Q24186190-9553135E-4C6A-4D3A-A224-5E2FFF427DDDQ24188295-0E60943A-13C8-4165-A7B6-1BF5B5A3FD6CQ35956673-85F6E96C-80A9-4F75-B1F4-5D0D0D3CC3BAQ36823607-A98AFD78-3165-4EE1-8BC8-4F6F9F86BE52Q37226646-06C800D7-3F57-4F8D-8F96-9CE5F4EC8946Q37702430-6B00589B-BAF7-4001-8A40-976F4B0D1E88Q38120592-8344149A-2A44-4B65-81BD-B5CCA9B71885Q38173104-3C053242-8FB7-4B5A-8684-BBBEEAABAD2BQ38202061-44F3C6B5-5F93-416D-8173-100D11542959Q38274588-2FA48E0D-EFFB-49DE-8CE8-D30F014BC206Q38345211-FE000C96-12DF-41B5-B6E3-2F22E071682BQ38565372-4ADA84E0-8868-42B3-9800-C5448BB35077Q38612818-E036E947-F666-408B-A497-965761D8ED63Q38627636-D6D8DBA0-B288-4B61-8C4C-86B2EA20788DQ38650689-5B47324C-1F78-4F29-A498-01BB1771E8FDQ38673385-5473962E-9409-47DD-BB07-F669885C672BQ38701535-A3B65983-15E2-4D47-BC66-95872DBE10E9Q38833116-67D3DC21-5DA9-4042-9844-1A68D81C884EQ38970783-0B9E9F89-5AAA-4465-AED2-3125288F3999Q39349302-E519378E-C8D8-4453-A26E-32BC0785C3AFQ39743020-A33AE763-52BE-4B92-B779-3419FFB4CED6Q40332155-8A21BA56-7BD9-47E9-8C2B-415916F1DBBBQ40386057-FB1B607F-E888-439B-8B5B-1401723E8F93Q40609636-57B19A23-95F8-43A1-B3E8-8C33D5E921D5Q40691705-293AB4DB-55C7-4A40-9316-1E5BADBC19E3Q40978380-70C6D923-D49C-4222-ACCE-FC1A79E56568Q41090088-D7588F78-99B9-4FE7-9C30-10EC94ED2B76Q41191641-A43466C5-34ED-4CBE-94BD-3A9AEA74EBBDQ41720426-37F4AE0C-72AE-424E-B64E-F8F135641B04Q41750995-BC5A6797-8759-4C22-92CD-76B1EAEA79E1Q41969159-AA3DB0BE-6915-4BCD-BD24-FEB2048B7E3EQ43840641-ABB336D5-45B0-4097-9D52-AC3C88A203B1Q44095571-C85A238A-AE45-4188-AE1C-15D5D8844F27Q44271139-8BA7B6E8-A162-4DA9-BBB3-227EC4F006B6Q44362389-B4184834-1B52-4307-8F50-3DC4A2C15A30Q44744528-89291EE1-AD96-4C2D-8D55-3AC594DC302EQ45335326-AE97F1AA-CA55-4D3E-94E5-706F9BF8C2E4Q46452798-E00B24BF-53CB-44F6-AB9E-EEFE7683713CQ47406507-B1B2E471-AEE2-47C9-8376-1551219B2AEDQ48625703-60D6FDBC-3E2E-4A2C-91DD-0127888883B5
P50
name
Laura-Maria Krabbe
@ast
Laura-Maria Krabbe
@en
Laura-Maria Krabbe
@nl
type
label
Laura-Maria Krabbe
@ast
Laura-Maria Krabbe
@en
Laura-Maria Krabbe
@nl
prefLabel
Laura-Maria Krabbe
@ast
Laura-Maria Krabbe
@en
Laura-Maria Krabbe
@nl